This segment focuses on the development, manufacturing, and commercialization of 3D bioprinting technologies and bioinks. Research and development efforts are directed towards creating advanced bioprinting systems like BIO X, BIO X6, INKREDIBLE, and Holograph X, which cater to diverse applications in tissue engineering, regenerative medicine, and drug discovery. The segment leverages technologies such as holographic stereolithography and microfluidics to achieve high-resolution bioprinting. These solutions enable the creation of complex 3D tissue models, impacting areas like personalized medicine and drug screening. The market positioning is strengthened through strategic partnerships and collaborations with research institutions and pharmaceutical companies, driving future growth and innovation in the field.

This segment is dedicated to developing and providing advanced tools for single-cell analysis and dispensing. The core technologies include Single-Cell Printer, C.SIGHT, B.SIGHT, and F.SIGHT, which enable precise isolation, dispensing, and analysis of individual cells. Research and development activities focus on improving the accuracy, throughput, and automation of these systems. These technologies are crucial for cell line development, single-cell genomics, and prokaryotic cell isolation. The segment serves pharmaceutical companies and research organizations, contributing to advancements in personalized medicine and drug discovery. Future opportunities lie in expanding the applications of single-cell technologies in areas such as cancer research and immunology, with a focus on improving patient outcomes through targeted therapies.

This segment specializes in developing and marketing liquid handling solutions and automation technologies for life science research. Key products include I-DOT, C.WASH, and other automated systems designed to improve the efficiency and accuracy of liquid handling tasks in laboratories. Research and development efforts are focused on enhancing the precision, speed, and scalability of these systems. These technologies are essential for drug discovery, genomics, and proteomics research. The segment serves pharmaceutical companies, research institutions, and diagnostic laboratories. Future growth potential lies in expanding the applications of automation technologies in areas such as high-throughput screening and personalized medicine, with a focus on improving research productivity and reducing costs.